Drug Trial Radar · NCT01349348
Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites
Last checked: Nov 20, 2026Latest source record: Oct 12, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
535
Actual
Start
Oct 2010
Primary completion
May 2012
Study completion Jul 2012
Sponsor
- Lead sponsor
- Otsuka Beijing Research InstituteOtsuka
- Sponsor type
- Industry
- First posted
- May 6, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of Tolvaptan 7.5mg and 15mg in treatment of patients with cirrhosis ascites who fail to response adequately to treatment with common diuretics.
Conditions
- Ascites
- Hepatic Cirrhosis
Interventions
TolvaptanDrug
tablet, 15 mg, Qd, for 7 days
TolvaptanDrug
tablet, 7.5 mg, Qd, for 7 days
placeboDrug
tablet, 7.5/15mg , Qd, 7days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in body weight after 7 days randomized treatment (Day 8).Time frame: 7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Renji Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.